Literature DB >> 27694180

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.

Harshad R Kulkarni1, Aviral Singh1, Christiane Schuchardt1, Karin Niepsch1, Manal Sayeg1, Yevgeniy Leshch2, Hans-Juergen Wester3, Richard P Baum4.   

Abstract

A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  PSMA; radioligand therapy; theranostics

Mesh：

Substances：

Year:  2016        PMID： 27694180     DOI： 10.2967/jnumed.115.170167

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  53 in total

Review 1.  History and future technical innovation in positron emission tomography.

Authors:  Terry Jones; David Townsend
Journal:  J Med Imaging (Bellingham)       Date:  2017-03-31

Review 2.  PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.

Authors:  R S Eapen; T C Nzenza; D G Murphy; M S Hofman; M Cooperberg; N Lawrentschuk
Journal:  World J Urol       Date:  2018-10-29       Impact factor: 4.226

3.  First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Authors:  Jie Zang; Xinrong Fan; Hao Wang; Qingxing Liu; Jingnan Wang; Hui Li; Fang Li; Orit Jacobson; Gang Niu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-08       Impact factor: 9.236

Review 4.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

Review 5.  A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.

Authors:  Amy Pawson; Zonia Ghumman; Phillip H Kuo; Hossein Jadvar; Twyla Bartel; Bobby Shayegan; Katherine Zukotynski
Journal:  Can Urol Assoc J       Date:  2020-04-01       Impact factor: 1.862

6.  [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Authors:  H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

Review 7.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Authors:  Shankar Siva; Cristian Udovicich; Ben Tran; Homi Zargar; Declan G Murphy; Michael S Hofman
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

8.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Authors:  Anna Yordanova; Paula Linden; Stefan Hauser; Michael Meisenheimer; Stefan Kürpig; Georg Feldmann; Florian C Gaertner; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-24       Impact factor: 9.236

9.  Current Status and Growth of Nuclear Theranostics in Singapore.

Authors:  Hian Liang Huang; Aaron Kian Ti Tong; Sue Ping Thang; Sean Xuexian Yan; Winnie Wing Chuen Lam; Kelvin Siu Hoong Loke; Charlene Yu Lin Tang; Lenith Tai Jit Cheng; Gideon Su Kai Ooi; Han Chung Low; Butch Maulion Magsombol; Wei Ying Tham; Charles Xian Yang Goh; Colin Jingxian Tan; Yiu Ming Khor; Sumbul Zaheer; Pushan Bharadwaj; Wanying Xie; David Chee Eng Ng
Journal:  Nucl Med Mol Imaging       Date:  2019-01-25

Review 10.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Authors:  Harshad R Kulkarni; Aviral Singh; Thomas Langbein; Christiane Schuchardt; Dirk Mueller; Jingjing Zhang; Coline Lehmann; Richard P Baum
Journal:  Br J Radiol       Date:  2018-06-01       Impact factor: 3.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.